5Zhang LH,Wu L,Raymon HK,et al. The synthetic compound CC- 5079 is potent inhibitor of tubulin polymerization andtumor necrosis factor-alpha production with anthumor activity. Cancer, 2006,66 (2) :951-959.
6Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared withearboplatin in patients with platinum-sensitive recur- rent ovarian cancer: An intergrouptrial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin 0ncol,2006,24 ( 29 ) : 4699-4707.
7Rebecca L, Siege M, Kimberly D, et al. Cancer Statistics,2016 [ J]. CA Cancer J Clin,2015,66( 1 ) :7-30.
8Celia D, Huang H, Homesley HD, et al. Patient-reported peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced endometrial cancer : Results from GOG 184 [ J ]. Gynecol Oncol, 2010, 119 ( 3 ) :538-542.
9Fleming GF,Brunetto VL,Cella D,et al. Phase III trial of doxorubi- tin plus cisplatin with or without paclitaxel plus filgrastim in ad- vanced endometrial carcinoma:a Gynecologic Ontology Group Study [ J]. J Clin Oncol,2004,22 ( 11 ) :2159-2166.
10Millel VF,Fleming RM,Cohn TM,et al. Randomized phase III non- inferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study [ J]. Gvnecol Oncol, 2012.125 ( 3 ):771.
